全文获取类型
收费全文 | 1051篇 |
免费 | 61篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 48篇 |
妇产科学 | 36篇 |
基础医学 | 125篇 |
口腔科学 | 6篇 |
临床医学 | 102篇 |
内科学 | 223篇 |
皮肤病学 | 9篇 |
神经病学 | 109篇 |
特种医学 | 147篇 |
外科学 | 78篇 |
综合类 | 51篇 |
预防医学 | 65篇 |
眼科学 | 1篇 |
药学 | 106篇 |
中国医学 | 4篇 |
肿瘤学 | 18篇 |
出版年
2021年 | 6篇 |
2020年 | 5篇 |
2019年 | 10篇 |
2018年 | 10篇 |
2017年 | 8篇 |
2016年 | 11篇 |
2015年 | 15篇 |
2014年 | 19篇 |
2013年 | 25篇 |
2012年 | 44篇 |
2011年 | 36篇 |
2010年 | 27篇 |
2009年 | 34篇 |
2008年 | 34篇 |
2007年 | 44篇 |
2006年 | 36篇 |
2005年 | 30篇 |
2004年 | 34篇 |
2003年 | 32篇 |
2002年 | 23篇 |
2001年 | 30篇 |
2000年 | 26篇 |
1999年 | 23篇 |
1998年 | 28篇 |
1997年 | 43篇 |
1996年 | 50篇 |
1995年 | 26篇 |
1994年 | 29篇 |
1993年 | 26篇 |
1992年 | 13篇 |
1991年 | 19篇 |
1990年 | 18篇 |
1989年 | 29篇 |
1988年 | 26篇 |
1987年 | 36篇 |
1986年 | 29篇 |
1985年 | 19篇 |
1984年 | 18篇 |
1983年 | 16篇 |
1982年 | 15篇 |
1981年 | 11篇 |
1980年 | 13篇 |
1979年 | 16篇 |
1978年 | 14篇 |
1977年 | 10篇 |
1976年 | 13篇 |
1975年 | 9篇 |
1974年 | 9篇 |
1969年 | 6篇 |
1967年 | 5篇 |
排序方式: 共有1129条查询结果,搜索用时 15 毫秒
1.
2.
The AMPA receptor potentiator LY404187 increases cerebral glucose utilization and c-fos expression in the rat. 总被引:3,自引:0,他引:3
Jill H Fowler Katherine Whalley Tracey Murray Michael J O'neill James McCulloch 《Journal of cerebral blood flow and metabolism》2004,24(10):1098-1109
AMPA receptor potentiators enhance AMPA receptor-mediated glutamatergic neurotransmission and may have therapeutic potential as cognitive enhancers or antidepressants. The anatomical basis for the action of AMPA receptor potentiators is unknown. The aim of this study was to determine the effects of the biarylpropylsulfonamide AMPA receptor potentiator, LY404187 (0.05 to 5 mg/kg subcutaneously), upon cerebral glucose utilization and c-fos expression using 14C-2-deoxglucose autoradiography and c-fos immunocytochemistry. LY404187 (0.5 mg/kg) produced significant elevations in glucose utilization in 28 of the 52 anatomical regions analyzed, which included rostral neocortical areas and the hippocampus, as well the dorsal raphe nucleus, lateral habenula, and locus coeruleus. No significant decreases in glucose utilization were observed in any region after LY404187 administration. The increases in glucose utilization with LY404187 (0.5 mg/kg) were blocked by pretreatment with the AMPA receptor antagonist LY293558 (25 mg/kg), indicating that LY404187 acts through AMPA receptor-mediated mechanisms. LY404187 (0.5 mg/kg) also produced increases in c-fos immunoreactivity in the cortex, locus coeruleus, and the dorsal raphe nucleus. These studies demonstrate neuronal activation in key brain areas that are associated with memory processes and thus provide an anatomical basis for the cognitive enhancing effects of AMPA receptor potentiators. 相似文献
3.
4.
5.
The hypothesis that the release of vasopressin-associated neurophysin (hNpI) or oxytocin-associated neurophysin (hNpII) is modified by a course of electroconvulsive therapy (ECT) was tested by the measurement of serum neurophysins before and after the first and last ECTs given to 17 unipolar depressed patients. Neither basal nor ECT-induced neurophysin release changed between the first and last ECTs. Data from the present study were combined with data from a previous published study to provide a sample of 29 unipolar depressed patients. In this extended sample, the release of hNpII after the first ECT was significantly correlated with improvement in symptoms of depression over a course of ECT as measured by the Hamilton Rating Scale for Depression and the Montgomery-Asberg Depression Rating Scale. 相似文献
6.
7.
We assessed the feasibility and psychometric properties of two commonly used health status questionnaires in Parkinson's disease (PD): the generic Nottingham Health Profile (NHP) and the disease-specific 39-item Parkinson's disease Questionnaire (PDQ-39), from a cross-sectional postal survey of PD patients (N = 81), using traditional and Rasch measurement methodologies. Overall response rate was 88%. Both questionnaires were found feasible, although the NHP performed less well. The PDQ-39 had fewer floor effects and was better able to separate respondents into distinct groups than the NHP, whereas the latter exhibited less ambiguous dimensionality and better targeting of respondents with non-extreme scores. Reliability and validity indices were similar, and potential differential item functioning by age and gender groups was found for both questionnaires. PDQ-39 response alternatives indicated ambiguity. With few exceptions, questionnaire scales were unable to meet recommended standards fully. While preliminary, this study illustrates the need for thorough evaluation of outcome measures and has implications beyond the questionnaires used here. Although promising, both questionnaires warrant further developmental work and stronger support of measurement validity before they could be considered fully suitable for valid use in PD, in particular in earlier stages of the disease. 相似文献
8.
9.
Melatonin suppression by bright light was investigated in 15 drug-free euthymic bipolar patients and control subjects matched for age and sex with the patients. There were no differences between groups on the extent of melatonin suppression by 500 lux bright light administered between 0200h and 0400h. These results do not support the hypothesis that melatonin suppression by bright light is a reliable trait marker in recovered bipolar patients. 相似文献
10.
John E. Geltosky Richard S. Smith Alice Whalley Gary Rhodes 《Journal of clinical laboratory analysis》1987,1(2):153-162
A simple enzyme immunoassay has been developed based on measuring antibodies to synthetic peptides corresponding to sequences in the Epstein-Barr nuclear antigen (EBNA). This assay, which is reproducible, quantitative, and simple to perform and interpret, can be an effective tool to aid in the diagnosis of infectious mononucleosis and nasopharyngeal carcinoma. 相似文献